【24h】

Dr Preskorn replies

机译:Preskorn博士回复

获取原文
获取原文并翻译 | 示例
           

摘要

Preskorn and colleagues1 reported on an impressively large population-based study among 900 patients who recently started venlafaxine treatment and who were both genotyped and phenotyped for cytochrome P450 (CYP) 2D6 metabolism. Among these patients, 3.9% and 27.0%, respectively, were genotyped and phenotyped as a poor metabolizer. The investigators inferred that "personalized medicine solely based on genetics can be misleading."(~p614) Although we agree with this statement, some issues could have been addressed more extensively to underscore the need for pharmacogenetics.
机译:Preskorn及其同事1在一项基于人群的研究中报告了一项令人印象深刻的大规模研究,研究对象是900位最近开始接受文拉法辛治疗且同时具有细胞色素P450(CYP)2D6代谢基因型和表型的患者。在这些患者中,基因型和表型分别为不良代谢者,分别为3.9%和27.0%。研究人员推断“仅基于遗传学的个性化医学可能会产生误导。”(〜p614)尽管我们同意这一说法,但某些问题本来可以得到更广泛的解决,以强调对药物遗传学的需求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号